Intuitive Surgical (ISRG)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$427.30-1.28%
Close 2026-07-07 · 1-day change
Reading ISRG? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ISRG free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading ISRG? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ISRG free→Warn: Management is running behind on a stated commitment.
Intuitive Surgical grows da Vinci procedures about 16% yearly. Profit margins stay near 68%. The company actively buys back shares, returning value. It leads in robotic surgery with strong demand.
Growth may slow due to below-consensus forecasts. Margin pressure could rise from reuse concerns. The stock is expensive with a high price-to-earnings ratio.
The price is about 8% above our fair value near $396. Analysts expect 16% revenue growth, which the market largely reflects. Our fair value is 30% below the Street median, showing some valuation caution.
Breaks if: procedure growth falls below 10% YoY next year
Focus on expanding the number of da Vinci procedures performed globally.
Stated in 3 of last 3 quarters. Da Vinci procedures grew approximately 16% in Q1 2026 compared to Q1 2025, indicating strong growth. The company is delivering on its priority to increase procedure volume.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Da Vinci procedures grew approximately 16% in Q1 2026.”
“Worldwide da Vinci procedure growth of approximately 17% to 17.5% in 2025.”
“Worldwide da Vinci procedure growth of approximately 15.5% to 17% in 2025.”
Breaks if: gross margin falls below 66% next year
Aim to sustain a stable gross profit margin within the guided range.
Stated in 3 of last 3 quarters. The company expects a non-GAAP gross profit margin of 67.5% to 68.5% in 2026. The margin guidance remains consistent, indicating a focus on maintaining profitability.
“Non-GAAP gross profit margin to be within a range of 67.5% and 68.5% of revenue in 2026.”
“Non-GAAP gross profit margin to be within a range of 67% and 68% of revenue in 2026.”
“Non-GAAP gross profit margin to be within a range of 67% and 67.5% of revenue in 2025.”
Breaks if: share repurchases drop below $500M per quarter next year
Continue the share repurchase program to return value to shareholders.
Stated in 2 of last 2 quarters. The company repurchased 2.3 million shares for $1.1 billion in Q1 2026, and the board increased the repurchase program to $5.0 billion. This indicates active capital allocation towards share buybacks.
“The Company repurchased 2.3 million shares for $1.1 billion in Q1 2026.”
“Board increased the authorized amount for the share repurchase program to $5.0 billion.”